Sofosbuvir: all 175 studies that test it

Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Hepatitis C Treatment in Idaho County JailsNot yet recruitingNCT06533319Not applicable
• Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected ChildrenRecruitingNCT05854511Phase 3
• Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
• Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedNCT04532931Phase 2Results posted
• Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT04211909Phase 3Results posted
• Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated CirrhosisCompletedNCT04112303Phase 3Results posted
• The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsCompletedNCT03819322Phase 2Results posted
• Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney TransplantCompletedNCT03619837Phase 4Results posted
• Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active InfectionCompletedNCT03512210Phase 4Results posted
• Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)CompletedNCT03501550Phase 2Results posted
• Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTerminatedNCT03487848Phase 2Results posted
• Ledipasvir/Sofosbuvir for Hepatitis B Virus InfectionCompletedNCT03312023Phase 2Results posted
• A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction ClinicCompletedNCT03235154Phase 4Results posted
• Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT03074331Phase 3Results posted
• Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C InfectionCompletedNCT03057847Phase 4Results posted
• Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal DiseaseCompletedNCT03036852Phase 2Results posted
• Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV InfectionCompletedNCT03022981Phase 2Results posted
• Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C CirrhosisCompletedNCT02994056Phase 2Results posted
• Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyCompletedNCT02939989Phase 3Results posted
• deLIVER: Direct Acting Antiviral Effects on the LiverCompletedNCT02938013Phase 4Results posted
• Hepatitis C Virus(HCV) Heart and Lung StudyCompletedNCT02858180Phase 4Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing RegimenCompletedNCT02822794Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver TransplantCompletedNCT02781571Phase 2Results posted
• Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceCompletedNCT02745535Phase 2Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV InfectionCompletedNCT02738333Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver TransplantationCompletedNCT02728206Phase 2Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus InfectionCompletedNCT02722837Phase 3Results posted
• Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) StudyTerminatedNCT02717949Phase 4Results posted
• A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C InfectionCompletedNCT02673489Phase 3Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCVCompletedNCT02671500Phase 3Results posted
• Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and CirrhosisCompletedNCT02639338Phase 3Results posted
• Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A InhibitorCompletedNCT02639247Phase 3Results posted
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyCompletedNCT02607800Phase 3Results posted
• Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)TerminatedNCT02503735Not applicableResults posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionCompletedNCT02480712Phase 3Results posted
• Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816CompletedNCT02468648Phase 2Results posted
• Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of CirrhosisTerminatedNCT02455167Phase 3Results posted
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected AdultsCompletedNCT02399345Phase 3Results posted
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionCompletedNCT02378961Phase 2Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)CompletedNCT02358044Phase 3Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02349048Phase 2Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV InfectionCompletedNCT02346721Phase 3Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 CirrhoticsCompletedNCT02304159Phase 4Results posted
• Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment StudyCompletedNCT02300103Phase 2Results posted
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedNCT02262728Phase 2Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionCompletedNCT02220998Phase 3Results posted
• Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionCompletedNCT02202980Phase 2Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV InfectionCompletedNCT02201953Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionCompletedNCT02201940Phase 3Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV InfectionCompletedNCT02175758Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)CompletedNCT02133131Phase 2Results posted
• Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With CirrhosisCompletedNCT02128542Phase 4Results posted
• Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) InfectionCompletedNCT02128217Phase 1Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding DisordersCompletedNCT02120300Phase 2Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without CirrhosisCompletedNCT02114177Phase 3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and CirrhosisCompletedNCT02114151Phase 3Results posted
• Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV InfectionCompletedNCT02074514Phase 3Results posted
• Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVCompletedNCT02032901Phase 3Results posted
• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.CompletedNCT02032888Phase 3Results posted
• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver TransplantCompletedNCT02032875Phase 3Results posted
• Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1CompletedNCT01994486Phase 2Results posted
• Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal InsufficiencyCompletedNCT01958281Phase 2Results posted
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV InfectionCompletedNCT01910636Phase 3Results posted
• Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionCompletedNCT01896193Phase 3Results posted
• Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVCompletedNCT01878799Phase 2Results posted
• Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionCompletedNCT01838590Phase 3Results posted
• Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV InfectionCompletedNCT01826981Phase 2Results posted
• Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3CompletedNCT01808248Phase 2Results posted
• A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01783678Phase 3Results posted
• Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionCompletedNCT01713283Phase 2Results posted
• Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver TransplantCompletedNCT01687270Phase 2Results posted
• Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver DecompensationCompletedNCT01687257Phase 2Results posted
• Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV InfectionCompletedNCT01682720Phase 3Results posted
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01667731Phase 3Results posted
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV InfectionCompletedNCT01641640Phase 3Results posted
• Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)CompletedNCT01604850Phase 3Results posted
• Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedNCT01565889Phase 1/2Results posted
• Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-TransplantCompletedNCT01559844Phase 2Results posted
• Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take InterferonCompletedNCT01542788Phase 3Results posted
• Phase 3 Study of Sofosbuvir and RibavirinCompletedNCT01497366Phase 3Results posted
• GS-7977 With Ribavirin for Hepatitis C (SPARE)CompletedNCT01441180Phase 1/2Results posted
• Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6CompletedNCT01329978Phase 2Results posted
• Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3CompletedNCT01260350Phase 2Results posted
• Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected PatientsCompletedNCT01188772Phase 2Results posted
• Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV PatientsCompletedNCT01054729Phase 2Results posted
• Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruitingNCT05992077Not applicable
• Effect of New Oral Treatment for Hepatitis C Virus on Seminal ParametersCompletedNCT05616598Phase 2/3
• Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated CirrhosisStatus unknownNCT05467826Phase 4
• Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During PregnancyActive, not recruitingNCT05140941Phase 4
• Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Status unknownNCT05016609Phase 4
• The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in ChinaStatus unknownNCT04997564Phase 4
• 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedNCT04885855Phase 2/3
• Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in EgyptCompletedNCT04773756Phase 4
• HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled TrialCompletedNCT04653818Phase 4
• COVID-19 Prophylaxis South Africa (COVER HCW)CompletedNCT04561063Phase 2

← Sofosbuvir overview